EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Complement Activation-Independent Attenuation of SARS-CoV-2 Infection by C1q and C4b-Binding Protein

Nazar Beirag, Praveen M Varghese iD, Martin Mayora Neto, Ahmad Al Aiyan, Haseeb A Khan iD, Moneeb Qablan, Mohamed H Shamji, Robert B Sim, Nigel Temperton iD, Uday Kishore iD

Viruses · 2023

DOI: 10.3390/v15061269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Nazar Beirag und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK. Hauptthemen laut MEDLINE: Complement C4b-Binding Protein, COVID-19. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, UAEU, Researchers Supporting Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The complement system is a key component of the innate immune response to viruses and proinflammatory events. Exaggerated complement activation has been attributed to the induction of a cytokine storm in severe SARS-CoV-2 infection. However, there is also an argument for the protective role of complement proteins, given their local synthesis or activation at the site of viral infection. This study investigated the complement activation-independent role of C1q and C4b-binding protein (C4BP) against SARS-CoV-2 infection. The interactions of C1q, its recombinant globular heads, and C4BP with the SARS-CoV-2 spike and receptor binding domain (RBD) were examined using direct ELISA. In addition, RT-qPCR was used to evaluate the modulatory effect of these complement proteins on the SARS-CoV-2-mediated immune response. Cell binding and luciferase-based viral entry assays were utilised to assess the effects of C1q, its recombinant globular heads, and C4BP on SARS-CoV-2 cell entry. C1q and C4BP bound directly to SARS-CoV-2 pseudotype particles via the RBD domain of the spike protein. C1q via its globular heads and C4BP were found to reduce binding as well as viral transduction of SARS-CoV-2 spike protein expressing lentiviral pseudotypes into transfected A549 cells expressing human ACE2 and TMPRSS2. Furthermore, the treatment of the SARS-CoV-2 spike, envelope, nucleoprotein, and membrane protein expressing alphaviral pseudotypes with C1q, its recombinant globular heads, or C4BP triggered a reduction in mRNA levels of proinflammatory cytokines and chemokines such as IL-1β, IL-8, IL-6, TNF-α, IFN-α, and RANTES (as well as NF-κB) in A549 cells expressing human ACE2 and TMPRSS2. In addition, C1q and C4BP treatment also reduced SARS-CoV-2 pseudotype infection-mediated NF-κB activation in A549 cells expressing human ACE2 and TMPRSS2. C1q and C4BP are synthesised primarily by hepatocytes; however, they are also produced by macrophages, and alveolar type II cells, respectively, locally at the pulmonary site. These findings support the notion that the locally produced C1q and C4BP can be protective against SARS-CoV-2 infection in a complement activation-independent manner, offering immune resistance by inhibiting virus binding to target host cells and attenuating the infection-associated inflammatory response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Complement C4b-Binding ProteinCOVID-19HumansComplement C1qAngiotensin-Converting Enzyme 2NF-kappa BSARS-CoV-2Spike Glycoprotein, CoronavirusComplement ActivationComplement System ProteinsProtein Binding

Stichwörter der Autor:innen

C1qC4BPCOVID-19SARS-CoV-2classical pathwaycomplementinnate immunity

Substanzen

Complement C4b-Binding Proteinspike protein, SARS-CoV-2Complement C1qAngiotensin-Converting Enzyme 2NF-kappa BSpike Glycoprotein, CoronavirusComplement System Proteins

Autor:innen und Institutionen

  • Biosciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK.
  • School of Biosciences and Technology, Vellore Institute of Technology, Vellore 632014, India.
  • Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich, Kent ME4 4TB, UK.
  • Department of Veterinary Medicine, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.
  • Department of Biochemistry, College of Science, King Saud University, Riyadh 4545, Saudi Arabia.
  • Immunomodulation and Tolerance Group, Department of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London SW7 2BX, UK.

ORCID-Profile: Praveen M Varghese, Haseeb A Khan, Nigel Temperton, Uday Kishore

Förderung

  • Wellcome Trust
  • UAEU
  • Researchers Supporting Project
  • King Saud University, Riyadh (HK)

Zitieren

APA

Beirag, N., Varghese, P. M., Neto, M. M., Al Aiyan, A., Khan, H. A., Qablan, M., Shamji, M. H., Sim, R. B., Temperton, N., & Kishore, U. (2023). Complement Activation-Independent Attenuation of SARS-CoV-2 Infection by C1q and C4b-Binding Protein. Viruses. https://doi.org/10.3390/v15061269

Vancouver

Beirag N, Varghese PM, Neto MM, Al Aiyan A, Khan HA, Qablan M, et al. Complement Activation-Independent Attenuation of SARS-CoV-2 Infection by C1q and C4b-Binding Protein. Viruses. 2023. doi:10.3390/v15061269

BibTeX
@article{Beirag2023,
  author = {Beirag, Nazar and Varghese, Praveen M and Neto, Martin Mayora and Al Aiyan, Ahmad and Khan, Haseeb A and Qablan, Moneeb and Shamji, Mohamed H and Sim, Robert B and Temperton, Nigel and Kishore, Uday},
  title = {Complement Activation-Independent Attenuation of SARS-CoV-2 Infection by C1q and C4b-Binding Protein},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15061269}
}
Kostenlos starten →